CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma

被引：0

作者：

Lin, Yi ^{[1
]}

Martin, Thomas ^{[2
]}

Usmani, Saad ^{[3
]}

Berdeja, Jesus ^{[4
]}

Jakubowiak, Andrzej ^{[5
]}

Agha, Mounzer ^{[6
]}

Cohen, Adam ^{[7
]}

Deol, Abhinav ^{[8
]}

Htut, Myo ^{[9
]}

Lesokhin, Alexander ^{[3
]}

Munshi, Nikhil ^{[10
]}

O'Donnell, Elizabeth ^{[11
]}

Jackson, Carolyn ^{[12
]}

Yeh, Tzu-Min ^{[12
]}

Banerjee, Arnob ^{[13
]}

Zudaire, Enrique ^{[13
]}

Madduri, Deepu ^{[12
]}

delCorral, Christopher ^{[14
]}

Pacaud, Lida ^{[14
]}

Jagannath, Sundar ^{[15
]}

机构：

[1] Mayo Clin, Rochester, MN USA

[2] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Univ Chicago, Chicago, IL USA

[6] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[7] Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

[8] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[9] City Hope Comprehens Canc Ctr, Duarte, CA USA

[10] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[11] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA

[12] Janssen Res & Dev, Raritan, NJ USA

[13] Janssen Res & Dev, Spring Hill, PA USA

[14] Legend Biotech, Somerset, NJ USA

[15] Mt Sinai Med Ctr, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

CAR-T cell therapy; cilta-cel; multiple myeloma; Phase I/II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-309

引用

页码：S488 / S489

页数：2

共 50 条

[41] Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
Shinsuke Iida
Kenshi Suzuki
Shigeru Kusumoto
Masaki Ri
Nobuhiro Tsukada
Yu Abe
Masayuki Aoki
Mitsuo Inagaki
International Journal of Hematology, 2017, 106 : 541 - 551
[42] Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
Iida, Shinsuke
Suzuki, Kenshi
Kusumoto, Shigeru
Ri, Masaki
Tsukada, Nobuhiro
Abe, Yu
Aoki, Masayuki
Inagaki, Mitsuo
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (04) : 541 - 551
[43] Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial
Maruyama, Dai
Tobinai, Kensei
Chou, Takaaki
Taniwaki, Masafumi
Shumiya, Yoshihisa
Iida, Shinsuke
CANCER SCIENCE, 2018, 109 (10): : 3245 - 3252
[44] DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
Khouri, Jack
Faiman, Beth M.
Grabowski, Dale
Mahfouz, Reda Z.
Khan, Shahper N.
Wei, Wei
Valent, Jason
Dean, Robert
Samaras, Christy
Jha, Babal K.
Lazarus, Hillard
Campagnaro, Erica L.
Malek, Ehsan
Reed, Janice
Karam, Mary Ann
Hamilton, Kimberly
Fada, Sherry
Kalaycio, Matt
Liu, Hien
Sobecks, Ronald
Saunthararajah, Yogen
Chew, Yap
Orloff, Mohammed
Reu, Frederic J.
SEMINARS IN HEMATOLOGY, 2021, 58 (01) : 45 - 55
[45] A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
Berenson, J. R.
Yellin, O.
Kazamel, T.
Hilger, J. D.
Chen, C-S
Cartmell, A.
Woliver, T.
Flam, M.
Bravin, E.
Nassir, Y.
Vescio, R.
Swift, R. A.
LEUKEMIA, 2012, 26 (07) : 1675 - 1680
[46] Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma
White, Darrell
Kassim, Adetola
Bhaskar, Birbal
Yi, Jing
Wamstad, Karen
Paton, Virginia E.
CANCER, 2013, 119 (02) : 339 - 347
[47] A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
J R Berenson
O Yellin
T Kazamel
J D Hilger
C-S Chen
A Cartmell
T Woliver
M Flam
E Bravin
Y Nassir
R Vescio
R A Swift
Leukemia, 2012, 26 : 1675 - 1680
[48] Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison
Bar, Noffar
Diels, Joris
van Sanden, Suzy
Mendes, Joao
Hernando, Teresa
Burnett, Heather
Cost, Patricia
Schecter, Jordan M.
Lendvai, Nikoletta
Patel, Nitin
Ishida, Tadao
Er, Jeremy
Harrison, Simon J.
Lopez-Munoz, Nieves
CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (09) : 1597 - 1603
[49] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
Dunn, Tamara J.
Dinner, Shira
Price, Elizabeth
Coutre, Steven E.
Gotlib, Jason
Hao, Ying
Berube, Caroline
Medeiros, Bruno C.
Liedtke, Michaela
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
[50] Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study
Andreozzi, Fabio
Dragani, Matteo
Quivoron, Cyril
Le Bras, Fabien
Assi, Tarek
Danu, Alina
Belhadj, Karim
Lazarovici, Julien
Cotteret, Sophie
Bernard, Olivier A.
Ribrag, Vincent
Michot, Jean-Marie
CANCERS, 2023, 15 (05)

← 1 2 3 4 5 →